Santo Holding AG
Investment Details
Investor Type
Family Office
Asset Class Focus
Private Equity, Venture Capital
Stage Focus
Seed, Early Stage, Growth, Late Stage
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, China, India, Brazil, France, Italy, Denmark, Switzerland, Spain, South Korea, Netherlands, Sweden, Belgium, Norway, Finland
Industries Focus
- Healthcare
- Life Sciences
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Medical Research
- Clinical Trials
- Regenerative Medicine
- Immunotherapy
- Oncology
- Neurology
- Cardiology
- Healthcare IT
Investment Size:
1,000,000 to 50,000,000 USD
Investor Details Founded: 2001
Santo Holding AG is a Zurich-based investment firm specializing in the biotechnology, pharmaceutical, life sciences, and healthcare sectors. The firm invests patient capital across these industries, supporting companies from early research through commercial expansion. Founded in 2001, Santo Holding is a multi-family office that stems from the wealth generated by German entrepreneurs Andreas and Thomas Strüngmann, who sold generic drugmaker Hexal to Novartis for $7 billion in 2005.
The firm's investment strategy focuses on providing long-term capital to innovative companies in the healthcare sector. Santo Holding supports ventures at various stages, from seed to late-stage growth, with investments ranging from $1 million to $50 million. The firm has a global geographical focus, with investments in countries such as Germany, Switzerland, the United States, China, India, Brazil, South Korea, Japan, the United Kingdom, France, Italy, Spain, the Netherlands, Belgium, Sweden, Denmark, Norway, Finland, Australia, and Canada.
Santo Holding's portfolio includes companies across various industries within the healthcare sector, such as biotechnology, pharmaceuticals, life sciences, medical devices, diagnostics, digital health, healthcare IT, medical research, clinical trials, regenerative medicine, immunotherapy, oncology, neurology, and cardiology. The firm's approach emphasizes supporting companies that are at the forefront of innovation in these fields, aiming to improve patient outcomes and advance medical treatments.
Requirements
- Innovative healthcare solutions
- Strong management teams
- Scalable business models
- Potential for significant impact on patient care
- Alignment with Santo Holding's investment strategy
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Contact Number Hidden]
Claim this Investor
Are you an official representative of Santo Holding AG?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim